BIOCHEMICAL-CHANGES AND MORPHOLOGICAL ALTERATIONS OF LIVER AND KIDNEY IN HAMSTERS AFTER ADMINISTRATION OF THE HMG-COENZYME-A REDUCTASE INHIBITOR, SIMVASTATIN - PREVENTION AND REVERSIBILITY BY MEVALONATE

被引:11
作者
OMS, P [1 ]
ASSIE, N [1 ]
BRUNIQUEL, F [1 ]
DEGRYSE, AD [1 ]
VANHAVERBEKE, G [1 ]
DELHON, A [1 ]
机构
[1] VET COLL TOULOUSE,TOULOUSE,FRANCE
来源
PHARMACOLOGY & TOXICOLOGY | 1995年 / 77卷 / 06期
关键词
D O I
10.1111/j.1600-0773.1995.tb01048.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The present study analyses the effects of simvastatin, a specific inhibitor of the 3-hydroxy-3-methylglutarylcoenzyme A (HMG-CoA reductase) in male Syrian hamsters fed a standard diet or a diet supplemented with 0.12% cholesterol and 20% coconut oil. In hamsters fed the standard diet, gastric administration of simvastatin (10 mg/kg/day) during 12 days was found to be lethal and to have hepatotoxic and nephrotoxic effects. This toxicity was exacerbated in hamsters fed a hyperlipidaemic diet and was preceded by a progressive anorexia and loss of body weight. Marked elevations in serum aspartate and alanine aminotransferase activities were associated with the organ lesions. All elevated biochemical changes and morphological alterations were prevented or reversed by coadministration of mevalonate, the product of the HMG-CoA reductase. It is suggested that the dramatic effect of simvastatin could result from depletion of a non-sterol metabolite of mevalonate in spite of a lack of protective effects of farnesol and geranylgeraniol in the following study. The toxicity of simvastatin could indeed result from the low basal activity of HMG-CoA reductase in hamster liver coupled with a prolonged inhibition of mevalonate synthesis.
引用
收藏
页码:391 / 396
页数:6
相关论文
共 28 条
[1]   LOVASTATIN IS HYPERTRIGLYCERIDEMIC IN SYRIAN GOLDEN-HAMSTERS [J].
AMIN, D ;
GUSTAFSON, S ;
PERRONE, MH .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1988, 157 (02) :530-534
[2]   LONG-TERM SAFETY AND EFFICACY PROFILE OF SIMVASTATIN [J].
BOCCUZZI, SJ ;
BOCANEGRA, TS ;
WALKER, JF ;
SHAPIRO, DR ;
KEEGAN, ME .
AMERICAN JOURNAL OF CARDIOLOGY, 1991, 68 (11) :1127-1131
[3]   LONG-TERM EXPERIENCE WITH SIMVASTATIN [J].
BOCCUZZI, SJ ;
KEEGAN, ME ;
HIRSCH, LJ ;
SHAPIRO, DR ;
PLOTKIN, DJ ;
MITCHEL, YB .
DRUG INVESTIGATION, 1993, 5 (02) :135-140
[4]  
BROWN MS, 1980, J LIPID RES, V21, P505
[5]   RELATIONSHIP BETWEEN MEVALONATE PATHWAY AND ARTERIAL MYOCYTE PROLIFERATION - IN-VITRO STUDIES WITH INHIBITORS OF HMG-COA REDUCTASE [J].
CORSINI, A ;
MAZZOTTI, M ;
RAITERI, M ;
SOMA, MR ;
GABBIANI, G ;
FUMAGALLI, R ;
PAOLETTI, R .
ATHEROSCLEROSIS, 1993, 101 (01) :117-125
[6]   REGULATION OF INTRACELLULAR ACTIN POLYMERIZATION BY PRENYLATED CELLULAR PROTEINS [J].
FENTON, RG ;
KUNG, HF ;
LONGO, DL ;
SMITH, MR .
JOURNAL OF CELL BIOLOGY, 1992, 117 (02) :347-356
[7]   ANIMAL SAFETY AND TOXICOLOGY OF SIMVASTATIN AND RELATED HYDROXY-METHYLGLUTARYL-COENZYME-A REDUCTASE INHIBITORS [J].
GERSON, RJ ;
MACDONALD, JS ;
ALBERTS, AW ;
KORNBRUST, DJ ;
MAJKA, JA ;
STUBBS, RJ ;
BOKELMAN, DL .
AMERICAN JOURNAL OF MEDICINE, 1989, 87 (4A) :S28-S38
[8]  
Glomset J. A., 1991, CURR OPIN LIPIDOL, V2, P118
[9]   3-HYDROXY-3-METHYLGLUTARYL - COENZYME-A REDUCTASE INHIBITORS IN THE TREATMENT OF HYPERCHOLESTEROLEMIA [J].
HOEG, JM ;
BREWER, HB .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1987, 258 (24) :3532-3536
[10]  
HOFFMAN WF, 1986, J MED CHEM, V29, P849, DOI 10.1021/jm00155a040